COMMUNIQUÉS West-GlobeNewswire

146,000 Orion Corporation A shares converted into B shares
01/08/2017
ORION CORPORATION STOCK EXCHANGE RELEASE 1 AUGUST 2017 at 9.00 a.m. EEST 146,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 146, [...]
Transparency Information
31/07/2017
PRESS RELEASE REGULATED INFORMATION Transparency Information Leuven (BELGIUM) - July 28, 2017, 22:01h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of [...]
Sanofi: Online Availability of Sanofi Group's Half-Year Financial Report for 2017
31/07/2017
Online Availability of Sanofi Group's Half-Year Financial Report for 2017 Paris, France - July 31, 2017 - Sanofi announces that its half-year financial report for the period ending June 30, 2017 is now available and has [...]
Sanofi : Mise en ligne du rapport financier semestriel 2017
31/07/2017
Mise en ligne du rapport financier semestriel 2017 Paris, France - Le 31 juillet 2017 - Sanofi annonce aujourd'hui avoir mis à la disposition du public et déposé auprès de l'Autorité des marchés financiers (AMF) son [...]
Oriola Corporation - Repurchase of own shares on 31 July 2017
31/07/2017
ORIOLA CORPORATION STOCK EXCHANGE RELEASE 31 JULY 2017 AT 18:45 EEST In the Nasdaq Helsinki Date 31July 2017 Exchange transaction Buy Share trading code OKDBV Amount, shares 13 203 Average price/share, EUR 3.6158 Total [...]
Summit Therapeutics plc : Total voting rights
31/07/2017
Summit Therapeutics plc ('Summit' or 'the Company') TOTAL VOTING RIGHTS Oxford, UK, 31 July 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), make the following announcement that for the purposes of the [...]
Ossur Hf : Transactions in relation to share buyback program
31/07/2017
Announcement from Össur hf. No. 54/2017 Reykjavík, 31 July 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Novo Nordisk A/S - Share repurchase programme
31/07/2017
Bagsværd, Denmark, 31 July 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
American Journal of Psychiatry Publishes Minerva Neurosciences' MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia
31/07/2017
WALTHAM, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, [...]
Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing
31/07/2017
DUBLIN - July 31, 2017 - Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic [...]
RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease
31/07/2017
The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US [...]
EDAP Announces filing of 510(k) Application for Ablatherm-Fusion® device
31/07/2017
LYON, France, July 31, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company submitted a 510(k) application for its Ablatherm Fusion device, enabling a more [...]
Spark Therapeutics Submits Marketing Authorization Application to European Medicines Agency for Investigational LUXTURNA(TM) (voretigene neparvovec)
31/07/2017
Potential for first gene therapy for a genetic disease to be approved in both the U.S. and EU PHILADELPHIA, July 31, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company [...]
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
31/07/2017
ProMIS' shareholders show overwhelming support for all resolutions TORONTO and CAMBRIDGE, Mass., July 31, 2017 - ProMIS Neurosciences, Inc. (the "Company"), a biotechnology company focused on the discovery and [...]
uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B
31/07/2017
~ Company now owns full global rights to late-stage program with clinical proof-of-concept ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 31, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene [...]
Arix Bioscience Half Yearly Report for the Six Months Ended 30 June 2017
31/07/2017
Arix Bioscience Half Yearly Report for the Six Months Ended 30 June 2017 Transformative period with good progress across the business LONDON, 31 July 2017: Arix Bioscience plc (LSE:ARIX) ("Arix Bioscience", "Arix" or [...]
Passing of Zealand Pharma A/S Extraordinary General Meeting on 31 July 2017
31/07/2017
Company announcement - No. 28/ 2017 Passing of Zealand Pharma A/S Extraordinary General Meeting on 31 July 2017 Copenhagen, 31 July 2017 - Today, Zealand Pharma A/S (Zealand) (CVR-no. 20 04 50 78) held an extraordinary [...]
Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases
31/07/2017
Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases The third dosing cohort has been completed and 24 patients have now been dosed . KY1005-CT01 clinical study is [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
31/07/2017
FIT Biotech Oy Company release July 31, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]

Pages